Related Experiment Video
Updated: Jul 5, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications
1Hospital Clinic, Division of Medical Oncology, IDIBAPS, Institut Clinic Malalties Hemato-Oncològiques (ICMHO), University of Barcelona, 08036 Barcelona, Spain. gascon@clinic.ub.es
Abstract:
Certain studies in which erythropoiesis-stimulating agents (ESAs) have been given not with the aim of correcting anemia but to achieve higher target levels of hemoglobin have shown significantly poorer survival among treated patients. However, studies in which ESAs were administered with the aim of reducing the need for RBC transfusions in patients with chemotherapy-associated anemia demonstrate that the use of these agents is not associated with any adverse effect on survival when compared with placebo controls. We can therefore be reassured that using ESAs within the labeled indications will not adversely affect patient outcome.
Related Concept Videos
Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
FDA Approved Drugs: Changes to Approved Drugs
Clinical Trials: Overview
Erythropoiesis
Erythropoiesis
Clinical Trials
There are four phases in a clinical trial. A phase one...